Neumora Therapeutics, Inc. (NMRA) stock
NMRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.43−0.00 (-0.95%)
Close on Nov 13, 2026Market cap $80.59MP/E –Yield –
Neumora Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Neumora Therapeutics's total assets was $125.25M at Jun 30, 2026. For fiscal 2025 it was $191.05M, down 39.7% from the year before.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $191.05M | -39.7% |
| FY2024 | Dec 31, 2024 | $316.97M | -36.1% |
| FY2023 | Dec 31, 2023 | $496.20M | +16.4% |
| FY2022 | Dec 31, 2022 | $426.23M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $125.25M | -44.0% |
| Q1 FY2026 | Mar 31, 2026 | $153.88M | -40.1% |
| Q4 FY2025 | Dec 31, 2025 | $191.05M | -39.7% |
| Q3 FY2025 | Sep 30, 2025 | $177.83M | -49.6% |
| Q2 FY2025 | Jun 30, 2025 | $223.83M | -44.7% |
| Q1 FY2025 | Mar 31, 2025 | $256.75M | -43.0% |
| Q4 FY2024 | Dec 31, 2024 | $316.97M | -36.1% |
| Q3 FY2024 | Sep 30, 2024 | $352.54M | -35.3% |
| Q2 FY2024 | Jun 30, 2024 | $404.47M | -5.1% |
| Q1 FY2024 | Mar 31, 2024 | $450.21M | – |
| Q4 FY2023 | Dec 31, 2023 | $496.20M | – |
| Q3 FY2023 | Sep 30, 2023 | $544.75M | – |
| Q4 FY2022 | Dec 31, 2022 | $426.23M | – |
See a number that looks wrong?